Clinical Trials Logo

Blepharitis clinical trials

View clinical trials related to Blepharitis.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06400511 Recruiting - Blepharitis Clinical Trials

A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

Start date: April 22, 2024
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the efficacy and safety of Pimecrolimus 0.3% (MR-139) Ophthalmic Ointment.

NCT ID: NCT06235450 Recruiting - Clinical trials for MicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye Syndrome

A Usability Study of iTEAR100 For Combined EyeLid Microblepharoexfoliation and Neurostimulation

Start date: January 19, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the usability of the iTEAR100 generation 2 device in combination with its newly developed iLIDS100 disposable cover.

NCT ID: NCT06182358 Recruiting - Demodex Blepharitis Clinical Trials

Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

Ariel
Start date: December 27, 2023
Phase: Phase 4
Study type: Interventional

To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.

NCT ID: NCT05608980 Recruiting - Blepharitis Clinical Trials

0.01% Hypochlorous Acid in the Treatment of Blepharitis

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This is a multi-center, multidisciplinary, open-label, randomized controlled prospective clinical study.

NCT ID: NCT05160623 Recruiting - Clinical trials for Anterior Blepharitis

Treatment of Blepharitis With Povidone-Iodine 1%

Start date: August 16, 2021
Phase: N/A
Study type: Interventional

One hundred blepharitis patients will be recruited. Each patient will treat one eye once daily with 1% PVI for 30 days by scrubbing the eyelid margin with the solution. The fellow eye will serve as the control and be given the standard treatment (commercial eye wipes). Before treatment initiation, various ocular surface variables will be assessed, such as dry eye grading, subjective discomfort scales, ocular surface questionnaire, and other clinical signs. After 30 days, an identical evaluation will be performed.

NCT ID: NCT05139511 Recruiting - Clinical trials for Meibomian Gland Dysfunction

Analysis of the Results of Intense Pulsed Light Treatment Previously to Laser Refractive Surgery

Start date: February 15, 2021
Phase: N/A
Study type: Interventional

Dry eye is often reported as the most common complication after a laser refractive surgery. Any refractive procedure can lead an impact on the corneal surface and the tear film. The main cause of this dry eye is the corneal denervation caused by the destruction of the anterior stromal nerves during the ablative procedure. This loss of corneal sensitivity leads to a decrease in the blink reflex, a decrease in the secretion rate of the meibomian glands and finally an evaporated dry eye. There is also a chronic inflammation at the corneal surface that produces an increase of inflammatory cytokines and a dysfunction of the meibomian glands. Yu et al have described incidences of dry eye closed to 60% after the first month of LASIK. Hovanesian et al have observed dry eye symptoms in 50% of patients 6 months after surgery. Donnenfeld et al describe 15% of moderate dry eye in the following 3 months and 5% of severe dry eye in the first 6 months. A small number of patients will present with chronic dry eye symptoms for more than 1 year. Bower et al analyzed its incidence in 0.8% Alterations in the tear film also decrease the quality of the retinal image and produce greater number of high-order due to the irregular. Pulsed light therapy (IPL) applied preoperatively in patients who undergo a laser refractive surgery may prevent the post-surgical dry eye and improve the refractive results. The aim of our study is to evaluate the usefulness of the applied therapy for the prevention of dry eye in patients that undergo a corneal refractive procedure.

NCT ID: NCT04858113 Recruiting - Blepharitis Clinical Trials

Short-term Effects on Tear Film (Baby Shampoo vs Blephasol)

Blepha
Start date: October 1, 2018
Phase: N/A
Study type: Interventional

Lid cleansing is the standard regime that is recommended for the management of blepharitis in the UK and beyond. Whilst many successful commercial preparations exist, and some with clinical evidence, professional guidelines (UK Royal College of Ophthalmologists, UK College of Optometrists, AAO, etc.) continue to advocate the use of a diluted solution of baby shampoo, despite no clinical evidence of its safety, tolerance or long term effectiveness, and despite a statement form the manufacturers that it should not be used for this purpose. Where licensed, registered products exist it seems bizarre that we have this situation, but a Cochrane review from 2012 indicated that only a longitudinal, randomized controlled trial against baby shampoo would alter their conclusions. Whilst that sort of clinical study is possible, it is proposed here to start with a short-term study to look at the immediate changes induced in the tear film and ocular surface when comparing baby shampoo with Blephasol solution, in a blind, randomized controlled trial.

NCT ID: NCT04742855 Recruiting - Blepharitis Clinical Trials

Probiotics for Blepharitis in Adults and Children

Start date: January 18, 2021
Phase:
Study type: Observational

The alteration of the intestinal microbiota through the use of specific probiotics can improve the clinical course of blepharitis by restoring intestinal and immune homeostasis. The purpose of this study is to define the possible positive impact of probiotics on patients with blepharitis.

NCT ID: NCT04603222 Recruiting - Blepharitis Clinical Trials

Evaluation of SUMMIT BRUSH in Treatment of Blepharitis

Start date: July 21, 2020
Phase: N/A
Study type: Interventional

Dry Eye Disease (DED) is a multifactorial disease that affects ~15-30 million people in the USA alone. It creates an enormous societal and economic burden, decreases productivity in the workplace, and affects the quality of lives of the people affected by this disease. DED is primarily caused by blepharitis, a chronic inflammation of the eyelid margins. If left untreated, blepharitis results in the obstruction and loss of the glands responsible for tear film production. The standard of care is the use of self-administered at home commercially available products, e.g., eyelid foams, gels, and pads. Although these products are helpful, they have limitations. Patients often require expensive in office procedures, e.g., lid debridement with exfoliation devices or more expensive procedures. The scope of this project is to evaluate the effectiveness of a new self-administered disposable ocular brush used in conjunction with the most common eyelid cleanser. The investigators are looking to see if combining the microexfoliation provided by the brush with the eyelid cleanser is more effective at removing the eyelid debris than the cleanser alone.

NCT ID: NCT04377841 Recruiting - Rosacea Clinical Trials

Facial Demodicosis and Ocular Demodicosis

Start date: April 13, 2020
Phase:
Study type: Observational

To understand the association between facial demodicosis and ocular demodicosis, we plan to enroll patients with facial demodicosis, ocular demodicosis, or both, in order to analyze their clinical presentations, the density of Demodex infestation over facial skin and eyelashes, and possible risk factors of the two diagnoses.